menu

MYR Pharmaceuticals — Treatment of HBV & HDV Infections

Career opportunities — Join our team! Privacy Policy

Mechanism of action

HomeBulevirtideMechanism of action
HomeBulevirtideMechanism of action

Mechanism of action


Bulevirtide is a novel drug candidate for treatment of chronic hepatitis B and chronic hepatitis delta and was originally developed by Professor Stephan Urban (University of Heidelberg, Germany).

Bulevirtide is a linear chemically synthesized lipopeptide bearing an N-terminal myristoyl moiety. It is composed of 47 naturally occurring L-amino acids derived from the Nterminal domain of the large hepatitis B virus (HBV) surface protein. This domain is responsible for the ability of HBV and hepatitis D virus (HDV) to bind hepatocyte receptors (NTCP, sodium taurocholate cotransporting polypeptide). 

Its antiviral mode of action relies on specific binding and blockage of the hepatocyte surface protein NTCP. Bulevirtide-mediated inhibition of NTCP prevents entry of HBV and HDV into the cell, hence infection of hepatocytes is prevented.